Related Experiment Video

Updated: Jun 17, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine

Hanlin L Wang1, Jean Lopategui, Mahul B Amin

  • 1Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Advances in Anatomic Pathology
|December 25, 2009
PubMed

Insights

KRAS mutational analysis is crucial for metastatic colorectal cancer (mCRC) treatment. Standardized testing ensures patients with wild-type KRAS tumors benefit from anti-EGFR therapies.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Gastroenterology

Background:

  • Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are effective for metastatic colorectal cancer (mCRC).
  • Clinical benefit from anti-EGFR therapies is limited to patients with wild-type KRAS tumors.
  • KRAS mutational status dictates patient eligibility for specific anti-EGFR treatments.

Purpose of the Study:

  • To highlight the importance of KRAS mutational analysis in mCRC management.
  • To emphasize the need for standardized KRAS testing and reporting procedures.
  • To define the central role of pathologists in KRAS testing and interpretation.

Main Methods:

  • Review of existing studies on anti-EGFR therapies and KRAS mutations in mCRC.
  • Analysis of current guidelines and recommendations for KRAS testing.
  • Discussion of the pathologist's role in specimen selection, laboratory choice, test selection, and result interpretation.

Main Results:

  • KRAS mutational analysis is essential for identifying patients who will benefit from anti-EGFR therapy.
  • Current approvals for panitumumab and cetuximab in mCRC are restricted to patients with wild-type KRAS.
  • Standardized KRAS testing is critical for optimizing patient care and treatment selection.

Conclusions:

  • KRAS mutational analysis is a key component in the management of mCRC.
  • Collaboration between pathologists and oncologists is vital for establishing standardized KRAS testing protocols.
  • Adherence to proposed guidelines will ensure consistent and accurate KRAS testing, improving patient outcomes.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...